Cargando…
T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065934/ http://dx.doi.org/10.1016/S1590-8658(22)00427-3 |
| _version_ | 1784699697599873024 |
|---|---|
| author | Cingolani, A. Felice, C. Lombardi, G. Onidi, F.M. Checchin, D. Colucci, R. Grossi, L. Ferronato, A. Rocchi, C. Ascolani, M. Binaghi, L. Dore, M.F. Fanini, L. Bulajic, M. Mocci, G. |
| author_facet | Cingolani, A. Felice, C. Lombardi, G. Onidi, F.M. Checchin, D. Colucci, R. Grossi, L. Ferronato, A. Rocchi, C. Ascolani, M. Binaghi, L. Dore, M.F. Fanini, L. Bulajic, M. Mocci, G. |
| author_sort | Cingolani, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9065934 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90659342022-05-04 T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY Cingolani, A. Felice, C. Lombardi, G. Onidi, F.M. Checchin, D. Colucci, R. Grossi, L. Ferronato, A. Rocchi, C. Ascolani, M. Binaghi, L. Dore, M.F. Fanini, L. Bulajic, M. Mocci, G. Dig Liver Dis Poster Presentations Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2022-05 2022-05-04 /pmc/articles/PMC9065934/ http://dx.doi.org/10.1016/S1590-8658(22)00427-3 Text en © 2022 Editrice Gastroenterologica Italiana S.r.l. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Poster Presentations Cingolani, A. Felice, C. Lombardi, G. Onidi, F.M. Checchin, D. Colucci, R. Grossi, L. Ferronato, A. Rocchi, C. Ascolani, M. Binaghi, L. Dore, M.F. Fanini, L. Bulajic, M. Mocci, G. T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY |
| title | T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY |
| title_full | T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY |
| title_fullStr | T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY |
| title_full_unstemmed | T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY |
| title_short | T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY |
| title_sort | t.06.4 long term efficacy and safety of abp 501 adalimumab biosimilar on inflammatory bowel diesases: the adaswitch study |
| topic | Poster Presentations |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065934/ http://dx.doi.org/10.1016/S1590-8658(22)00427-3 |
| work_keys_str_mv | AT cingolania t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT felicec t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT lombardig t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT onidifm t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT checchind t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT coluccir t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT grossil t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT ferronatoa t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT rocchic t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT ascolanim t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT binaghil t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT doremf t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT faninil t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT bulajicm t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy AT moccig t064longtermefficacyandsafetyofabp501adalimumabbiosimilaroninflammatoryboweldiesasestheadaswitchstudy |